Bispecific antibody · Immune activation, directed at epidermal growth factor receptor (EGFR) and CD3 · developed by Janux Therapeutics
JANX008 is a protease-activated, tumor-activated T-cell engager that binds EGFR on tumor cells and CD3 on T-cells once its masks are cleaved in the tumor microenvironment. Its albumin-binding domain extends circulating half-life. It is being studied in non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, colorectal carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05783622 | Phase 1 | Non-Small Cell Lung Cancer | Active not recruiting | JANX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal CarcinomaNon-Small Cell Lung CancerPancreatic Ductal AdenocarcinomaRenal Cell CarcinomaSmall Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckTriple-negative Breast Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the JANX page.
See JANX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JANX catalysts and pipeline →